CR20160497A - Derivados de diheterociclo enlazado a cicloalquilo - Google Patents

Derivados de diheterociclo enlazado a cicloalquilo

Info

Publication number
CR20160497A
CR20160497A CR20160497A CR20160497A CR20160497A CR 20160497 A CR20160497 A CR 20160497A CR 20160497 A CR20160497 A CR 20160497A CR 20160497 A CR20160497 A CR 20160497A CR 20160497 A CR20160497 A CR 20160497A
Authority
CR
Costa Rica
Prior art keywords
derivatives
linked
compounds
diheterociclo
cyclalkyl
Prior art date
Application number
CR20160497A
Other languages
English (en)
Spanish (es)
Inventor
Pei-Pei Kung
Lakshmi Sourirajan Narasimhan
Daniel Tyler Richter
Qinhua Huang
Paul Francis Richardson
Michael Raymond Collins
Samantha Elizabeth Greasley
Robert Louis Hoffman
Maria Angelica Linton
Graham Smith
Aaron Craig Burns
Robert Steven Kania
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CR20160497A publication Critical patent/CR20160497A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CR20160497A 2014-04-30 2015-04-17 Derivados de diheterociclo enlazado a cicloalquilo CR20160497A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461986876P 2014-04-30 2014-04-30
PCT/IB2015/052833 WO2015166373A1 (en) 2014-04-30 2015-04-17 Cycloalkyl-linked diheterocycle derivatives

Publications (1)

Publication Number Publication Date
CR20160497A true CR20160497A (es) 2016-12-20

Family

ID=53276932

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20160497A CR20160497A (es) 2014-04-30 2015-04-17 Derivados de diheterociclo enlazado a cicloalquilo

Country Status (40)

Country Link
US (4) US20170050958A1 (enExample)
EP (2) EP3137460B1 (enExample)
JP (2) JP6574203B2 (enExample)
KR (1) KR20160149256A (enExample)
CN (1) CN106232598B (enExample)
AP (1) AP2016009530A0 (enExample)
AU (1) AU2015254943B2 (enExample)
BR (1) BR112016024513A2 (enExample)
CA (1) CA2947130C (enExample)
CL (1) CL2016002532A1 (enExample)
CR (1) CR20160497A (enExample)
CU (1) CU24420B1 (enExample)
CY (1) CY1122439T1 (enExample)
DK (1) DK3137460T3 (enExample)
DO (1) DOP2016000293A (enExample)
EA (1) EA033919B1 (enExample)
EC (1) ECSP16083017A (enExample)
ES (1) ES2759434T3 (enExample)
GE (2) GEP20186879B (enExample)
GT (1) GT201600232A (enExample)
HR (1) HRP20192056T1 (enExample)
HU (1) HUE046518T2 (enExample)
IL (1) IL248629B (enExample)
LT (1) LT3137460T (enExample)
MA (2) MA49708A (enExample)
MD (1) MD20160111A2 (enExample)
MX (1) MX2016014143A (enExample)
NI (1) NI201600163A (enExample)
NZ (1) NZ725496A (enExample)
PE (1) PE20161436A1 (enExample)
PH (1) PH12016501997A1 (enExample)
PL (1) PL3137460T3 (enExample)
PT (1) PT3137460T (enExample)
RS (1) RS59617B1 (enExample)
SG (1) SG11201608634RA (enExample)
SI (1) SI3137460T1 (enExample)
SV (1) SV2016005310A (enExample)
TN (1) TN2016000459A1 (enExample)
UA (1) UA117861C2 (enExample)
WO (1) WO2015166373A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6783663B2 (ja) * 2014-01-06 2020-11-11 ライゼン・ファーマシューティカルズ・エスアー 新規グルタミナーゼ阻害剤
MA49708A (fr) 2014-04-30 2020-06-03 Pfizer Dérivés de dihétérocycle liés à cycloalkyle
CN107474024B (zh) * 2016-06-08 2022-12-13 北京赛林泰医药技术有限公司 一种谷氨酰酶抑制剂及其组合物和用途
CN110746416A (zh) * 2019-09-05 2020-02-04 中国药科大学 含有三氮唑结构的谷氨酰胺酶gls1抑制剂或其可药用的盐、其制备方法及用途
CN116023375A (zh) * 2021-10-25 2023-04-28 成都苑东生物制药股份有限公司 一种杂环类衍生物、其制备方法及用途

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2037257A1 (en) 1970-07-28 1972-02-03 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
WO1992020642A1 (en) 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
ATE503496T1 (de) 1992-02-06 2011-04-15 Novartis Vaccines & Diagnostic Biosynthetisches bindeprotein für tumormarker
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US5702637A (en) 1995-04-19 1997-12-30 Minnesota Mining And Manufacturing Company Liquid crystal compounds having a chiral fluorinated terminal portion
US5861510A (en) 1995-04-20 1999-01-19 Pfizer Inc Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
JPH09104838A (ja) 1995-10-09 1997-04-22 Mitsui Toatsu Chem Inc 水性塗料用樹脂組成物
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
PT780386E (pt) 1995-12-20 2003-02-28 Hoffmann La Roche Inibidores de metaloprotease de matriz
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
IL125954A (en) 1996-03-05 2003-06-24 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect
ATE227283T1 (de) 1996-07-13 2002-11-15 Glaxo Group Ltd Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
AU3693697A (en) 1996-07-13 1998-02-09 Glaxo Group Limited Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
CN1225639A (zh) 1996-07-18 1999-08-11 美国辉瑞有限公司 基于次膦酸酯的基质金属蛋白酶抑制剂
SK21499A3 (en) 1996-08-23 2000-05-16 Pfizer Arylsulfonylamino hydroxamic acid derivatives
EP0950059B1 (en) 1997-01-06 2004-08-04 Pfizer Inc. Cyclic sulfone derivatives
SK283963B6 (sk) 1997-02-03 2004-06-08 Pfizer Products Inc. Deriváty arylsulfonylaminohydroxamovej kyseliny, farmaceutický prostriedok, spôsob inhibície matričných metaloproteináz alebo produkcie faktora nekrózy nádorov
WO1998034915A1 (en) 1997-02-07 1998-08-13 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
JP3710489B2 (ja) 1997-02-11 2005-10-26 ファイザー・インク アリールスルホニルヒドロキサム酸誘導体
WO1998050356A1 (en) 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
WO1998054093A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
DE69838172T2 (de) 1997-08-22 2008-04-10 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
WO1999016755A1 (en) 1997-09-26 1999-04-08 Merck & Co., Inc. Novel angiogenesis inhibitors
JP2001522853A (ja) 1997-11-11 2001-11-20 ファイザー・プロダクツ・インク 抗癌剤として有用なチエノピリミジンおよびチエノピリジン誘導体
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
TR200003514T2 (tr) 1998-05-29 2002-05-21 Sugen Inc. Pirol ikame edilmiş 2-indolinon protein kinaz inhibitörleri
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
EP1292591B1 (en) 2000-06-22 2005-02-02 Pfizer Products Inc. Substituted bicyclic derivatives for the treatment of abnormal cell growth
US6451828B1 (en) 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
DE10109807A1 (de) 2001-03-01 2002-09-05 Wella Ag Verbrückte Diaminopyrazole und diese Verbindungen enthaltende Färbemittel
US7029729B2 (en) 2003-02-24 2006-04-18 3M Innovative Properties Company Cholesteric liquid crystal additives
ES2279446T3 (es) 2003-08-15 2007-08-16 MERCK & CO., INC. Antagonistas nmda/nr2b de 4-cicloalquilaminopirazolo pirimidina.
WO2006028269A2 (en) 2004-09-09 2006-03-16 Astellas Pharma Inc. Thiazole derivatives having vap-1 ihibitory activity
EP2137158A4 (en) 2007-02-28 2012-04-18 Methylgene Inc LOW-MOLECULAR INHIBITORS OF PROTEINARGININE METHYLTRANSFERASES (PRMTS)
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
CN104220070B (zh) * 2011-11-21 2020-01-21 卡利泰拉生物科技公司 谷氨酰胺酶的杂环抑制剂
US9665874B2 (en) 2012-03-13 2017-05-30 American Express Travel Related Services Company, Inc. Systems and methods for tailoring marketing
WO2014031933A2 (en) 2012-08-24 2014-02-27 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
SMT202100589T1 (it) * 2012-11-16 2021-11-12 Calithera Biosciences Inc Inibitori di glutaminasi eterociclici
US10011574B2 (en) 2012-11-21 2018-07-03 Agios Pharmaceuticals, Inc. Glutaminase inhibitors and method of use
WO2014079011A1 (en) * 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US9029531B2 (en) * 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
JP6285950B2 (ja) 2012-12-03 2018-02-28 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼの複素環式阻害剤を用いるがんの処置
US9868705B2 (en) * 2013-09-27 2018-01-16 The Board Of Trustees Of The University Of Illinois Tetra-aryl cyclobutane inhibitors of androgen receptor action for the treatment of hormone refractory cancer
WO2015061432A1 (en) 2013-10-25 2015-04-30 Calithera Biosciences, Inc. Treatment of viral infections with inhibitors of glutaminase
JP6783663B2 (ja) * 2014-01-06 2020-11-11 ライゼン・ファーマシューティカルズ・エスアー 新規グルタミナーゼ阻害剤
EP3116872A4 (en) 2014-03-14 2017-08-30 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
CA2943339A1 (en) 2014-03-21 2015-09-24 Agios Pharmaceuticals, Inc. Compounds and their methods of use
MA49708A (fr) * 2014-04-30 2020-06-03 Pfizer Dérivés de dihétérocycle liés à cycloalkyle
SG11201610333VA (en) 2014-06-13 2017-01-27 Calithera Biosciences Inc Combination therapy with glutaminase inhibitors
WO2016014890A1 (en) 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
US20160287564A1 (en) 2015-03-30 2016-10-06 Calithera Biosciences, Inc. Methods of administering glutaminase inhibitors
JP6944377B2 (ja) 2015-04-06 2021-10-06 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼの阻害剤を用いる肺がんの処置
US10884952B2 (en) 2016-09-30 2021-01-05 Intel Corporation Enforcing memory operand types using protection keys
JP6943759B2 (ja) 2017-12-28 2021-10-06 株式会社東海理化電機製作所 シフト装置

Also Published As

Publication number Publication date
MD20160111A2 (ro) 2017-06-30
DK3137460T3 (da) 2019-12-16
UA117861C2 (uk) 2018-10-10
KR20160149256A (ko) 2016-12-27
ES2759434T3 (es) 2020-05-11
NZ725496A (en) 2019-11-29
CA2947130A1 (en) 2015-11-05
PE20161436A1 (es) 2017-01-08
EA033919B1 (ru) 2019-12-10
RS59617B1 (sr) 2020-01-31
GEP20186879B (en) 2018-07-10
HRP20192056T1 (hr) 2020-02-21
SI3137460T1 (sl) 2019-12-31
CN106232598B (zh) 2020-03-13
WO2015166373A1 (en) 2015-11-05
NI201600163A (es) 2016-11-25
MA49708A (fr) 2020-06-03
IL248629B (en) 2019-07-31
MA39926B1 (fr) 2019-12-31
TN2016000459A1 (en) 2018-04-04
US10125130B2 (en) 2018-11-13
PL3137460T3 (pl) 2020-04-30
CU24420B1 (es) 2019-06-04
CA2947130C (en) 2018-10-02
CL2016002532A1 (es) 2017-04-21
US20190270737A1 (en) 2019-09-05
EA201650003A1 (ru) 2017-03-31
US20180148441A1 (en) 2018-05-31
CU20160157A7 (es) 2017-05-10
JP2017514818A (ja) 2017-06-08
PH12016501997B1 (en) 2017-01-09
US20170050958A1 (en) 2017-02-23
US20190040055A1 (en) 2019-02-07
CN106232598A (zh) 2016-12-14
GEAP201814314A (en) 2018-03-26
AU2015254943A1 (en) 2016-10-27
US10676471B2 (en) 2020-06-09
HK1232212A1 (zh) 2018-01-05
EP3137460A1 (en) 2017-03-08
HUE046518T2 (hu) 2020-03-30
JP6574203B2 (ja) 2019-09-11
DOP2016000293A (es) 2016-12-30
PH12016501997A1 (en) 2017-01-09
SG11201608634RA (en) 2016-11-29
JP2019214597A (ja) 2019-12-19
ECSP16083017A (es) 2017-03-31
IL248629A0 (en) 2017-01-31
PT3137460T (pt) 2019-12-30
AP2016009530A0 (en) 2016-10-31
SV2016005310A (es) 2017-08-29
GT201600232A (es) 2019-10-10
EP3556757A1 (en) 2019-10-23
LT3137460T (lt) 2019-12-10
AU2015254943B2 (en) 2019-04-04
MX2016014143A (es) 2017-02-15
CY1122439T1 (el) 2020-11-25
BR112016024513A2 (pt) 2017-08-15
EP3137460B1 (en) 2019-10-23

Similar Documents

Publication Publication Date Title
NI201900013A (es) Inhibidor de piridopirimidinona cdk2/4/6
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
CO2017002998A2 (es) Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1
UY36170A (es) Compuestos de dihidroisoquinolinona sustituida
MX2016014547A (es) Compuestos para tratar atrofia muscular espinal.
UY40230A (es) Macrociclos con grupos P2’ heterocíclicos como inhibidores del factor XIa y composiciones farmacéuticas que los comprenden
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
DOP2015000157A (es) Lactamas fusionadas de arilo y heteroarilo
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CY1122439T1 (el) Κυκλοαλκυλ-συνδεδεμενα παραγωγα δι-ετεροκυκλων
UY36074A (es) ?derivados de dihidropirrolopirimidina? .
EA201791396A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
EA201791397A1 (ru) СВЯЗАННЫЕ С ГЕТЕРОЦИКЛИЛАМИ ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
CL2018002347A1 (es) Nuevos derivados pirrolidina
DOP2016000326A (es) Compuestos de dihidroisoquinolinona sustituida
ECSP17003149A (es) Compuestos de dihidroisoquinolinona sustituida
CU20140033A7 (es) Derivados de pirrolopirimidina y purina